Johnson & Johnson

$146.48
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.63 (-0.43%) As of 1:49 PM EDT today

Why Robinhood?

You can buy or sell JNJ and other stocks, options, ETFs, and crypto commission-free!

About JNJ

Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer, Pharmaceutical, and Medical Devices. Read More The Consumer segment includes products used in the baby care, oral care, beauty, over-the-counter pharmaceutical, women's health, and wound care markets. The Pharmaceutical segment focuses on therapeutic areas such as immunology, infectious diseases ad vaccines, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The Medical Devices segment offers products used in the orthopedic, surgery, cardiovascular, diabetes care, and eye health fields. The company was founded by Robert Wood Johnson I, James Wood Johnson and Edward Mead Johnson Sr. in 1886 and is headquartered in New Brunswick, NJ. The listed name for JNJ is Johnson & Johnson.

Employees
132,200
Headquarters
New Brunswick, New Jersey
Founded
1887
Market Cap
385.73B
Price-Earnings Ratio
25.60
Dividend Yield
2.69
Average Volume
6.86M
High Today
$147.92
Low Today
$146.06
Open Price
$147.60
Volume
2.78M
52 Week High
$157.00
52 Week Low
$109.16

Collections

Digestible Financial News

Jack Kramer & Nick Martell

Managing Editors of News & Snacks at Robinhood Financial LLC

JNJ News

MarketWatch21h

Johnson & Johnson stock rises Monday, still underperforms market

Shares of Johnson & Johnson JNJ, +0.99% inched 1.00% higher to $147.11 Monday, on what proved to be an all-around positive trading session for the stock market,
MarketWatchSep 26

There are four coronavirus vaccines in late-stage studies β€” here’s how they differ

Johnson & Johnson’s investigational COVID-19 vaccine entered Phase 3 clinical trials this week, making it the fourth vaccine candidate in the U.S. to do so and
ReutersSep 25

Positive results for J&J vaccine; child racial disparities seen

(Reuters) - The following is a roundup of some of the latest scientific studies on the novel coronavirus and efforts to find treatments and vaccines for COVID-1

JNJ Earnings

$0.00
$0.86
$1.72
$2.58
Q4 2018
Q1 2019
Q2 2019
Q3 2019
Q4 2019
Q1 2020
Q2 2020
Q3 2020
Estimated
β€” per share
Actual
Available Oct 13, Pre-Market

You May Also Like

More JNJ News

ReutersSep 25

Johnson & Johnson COVID-19 vaccine produces strong immune response in early trial

(Reuters) - A single dose of Johnson & Johnson's JNJ.N experimental COVID-19 vaccine produced a strong immune response against the novel coronavirus in an early
MarketWatchSep 25

J&J: most Phase 1/2a participants in COVID-19 vaccine developed neutralizing antibodies

Shares of Johnson & Johnson JNJ, +0.14% were up 0.1% in trading on Friday after data from the Phase 1/2a clinical trial for its COVID-19 vaccine candidate was p
BenzingaSep 24

Current Updates On COVID-19 Vaccine

Besides saving lives and the global economy, we are expecting three things from the upcoming COVID-19 vaccine: safety, immunogenicity and efficacy. But we never
New York TimesSep 23

Your Thursday Briefing

A single-shot vaccine enters final testing in the U.S. Johnson & Johnson has begun the final stage of clinical trials for a coronavirus vaccine that could have
BenzingaSep 23

Why Genmab's Stock Is Trading Lower Today

Genmab (NASDAQ: GMAB) shares are trading lower on Wednesday after the company announced legal arbitration with partner Johnson & Johnson (NYSE: JNJ) over Darzal
MarketWatchSep 23

Nike, Johnson & Johnson share gains lead the way, but Dow flat

The Dow Jones Industrial Average is climbing Wednesday morning with shares of Nike and Johnson & Johnson leading the way for the index. Shares of Nike NKE, +10.
ReutersSep 23

J&J kicks off study of single-shot COVID-19 vaccine in 60,000 volunteers

CHICAGO (Reuters) - Johnson & Johnson JNJ.N on Wednesday began a 60,000-person trial of an experimental single-shot COVID-19 vaccine that, if proven effective,
Robinhood Snacks newsletters and podcasts reflect the opinions of only the authors who are associated persons of Robinhood Financial LLC and do not reflect the views of Robinhood Markets, Inc. or any of its subsidiaries or affiliates. They are meant for informational purposes only, are not intended to serve as a recommendation to buy or sell any security in a self-directed Robinhood account or any other account, and are not an offer or sale of a security. They are also not research reports and are not intended to serve as the basis for any investment decision. Any third-party information provided therein does not reflect the views of Robinhood Markets, Inc., Robinhood Financial LLC, or any of their subsidiaries or affiliates. All investments involve risk and the past performance of a security or financial product does not guarantee future results or returns. Keep in mind that while diversification may help spread risk, it does not assure a profit or protect against loss. There is always the potential of losing money when you invest in securities or other financial products. Investors should consider their investment objectives and risks carefully before investing. The price of a given security may increase or decrease based on market conditions and customers may lose money, including their original investment. Robinhood Financial LLC, member FINRA/SIPC.

All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.